1-5 of 5
Megan Manuel, MSN
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

TCA Cycle Inhibition By Cpi-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML)

Timothy S Pardee, MD PhD, Lance D Miller, PhD, Kristin Pladna, MS, Scott Isom, MS, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, Dianna Howard, MD, Megan Manuel, MSN, Sarah Dralle, MSN, Susan Lyerly, PA-C, Bayard L Powell, MD
Journal: Blood
Blood (2016) 128 (22): 4062.
https://doi.org/10.1182/blood.V128.22.4062.4062
Published: 2016
Journal Articles

The Mitochondrial Metabolism Inhibitor Cpi-613 in Combination with High Dose Ara-C (HDAC) and Mitoxantrone Is Highly Active in Poor Risk Relapsed or Refractory Acute Myeloid Leukemia (AML)

Timothy Pardee, MD PhD, Kristin Pladna, MS, Scott Isom, MS, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, Dianna Howard, MD, Megan Manuel, MSN, Sarah Dralle, MSN, David D Hurd, MD, Susan Lyerly, PA-C, Bayard L Powell, MD
Journal: Blood
Blood (2015) 126 (23): 2556.
https://doi.org/10.1182/blood.V126.23.2556.2556
Published: 2015
Journal Articles

The Mitochondrial Metabolism Inhibitor Cpi-613 Is Highly Active in Combination with High Dose Ara-C (HiDAC) and Mitoxantrone in a Phase I Study for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Timothy S Pardee, MD PhD, Kristin Stadelman, MS, Scott Isom, MS, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, David D Hurd, MD, Robin Harrelson, BSN, Megan Manuel, MSN, Sarah Dralle, MSN, Susan Lyerly, PA, Bayard L. Powell, MD
Journal: Blood
Blood (2014) 124 (21): 3744.
https://doi.org/10.1182/blood.V124.21.3744.3744
Published: 2014
Journal Articles

High Dose Cytarabine, Mitoxantrone and L-Asparaginase (HAMA) Salvage For Relapsed Or Refractory Acute Myeloid Leukemia (AML) In The Elderly

Tamjeed Ahmed, MD, Scott Holwerda, MD, Timothy Pardee, MD, PhD, Scott Isom, MS, Susan Lyerly, PA, Leslie Renee Ellis, MD, Megan Manuel, MSN, Sarah Dralle, MSN, Berenzon Dmitriy, MD, Heidi D. Klepin, MD, MS, Bayard L. Powell, MD
Journal: Blood
Blood (2013) 122 (21): 2700.
https://doi.org/10.1182/blood.V122.21.2700.2700
Published: 2013
Journal Articles

A Phase I Study Of The Safety, Efficacy and Pharmacokinetics Of The First In Class Pyruvate Dehydrogenase Complex Inhibitor Cpi-613 In Patients With Advanced Hematologic Malignancies

Timothy Pardee, MD, PhD, King Lee, PhD, RAC, John Luddy, MS, Claudia Maturo, MS, Robert Rodriguez, BSc, MBA, Denise A Levitan, MD, David D Hurd, MD, Leslie Renee Ellis, MD, Scott Isom, MS, Robin Harrelson, BSN, Megan Manuel, MSN, Sarah Dralle, MSN, Susan Lyerly, PA, Bayard L. Powell, MD
Journal: Blood
Blood (2013) 122 (21): 486.
https://doi.org/10.1182/blood.V122.21.486.486
Published: 2013